Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19178525rdf:typepubmed:Citationlld:pubmed
pubmed-article:19178525lifeskim:mentionsumls-concept:C1556094lld:lifeskim
pubmed-article:19178525lifeskim:mentionsumls-concept:C0683971lld:lifeskim
pubmed-article:19178525lifeskim:mentionsumls-concept:C0032105lld:lifeskim
pubmed-article:19178525lifeskim:mentionsumls-concept:C0166417lld:lifeskim
pubmed-article:19178525lifeskim:mentionsumls-concept:C0033382lld:lifeskim
pubmed-article:19178525lifeskim:mentionsumls-concept:C0963992lld:lifeskim
pubmed-article:19178525lifeskim:mentionsumls-concept:C0017431lld:lifeskim
pubmed-article:19178525lifeskim:mentionsumls-concept:C0332281lld:lifeskim
pubmed-article:19178525lifeskim:mentionsumls-concept:C1319635lld:lifeskim
pubmed-article:19178525pubmed:issue3lld:pubmed
pubmed-article:19178525pubmed:dateCreated2009-8-25lld:pubmed
pubmed-article:19178525pubmed:abstractTextThe Ala allele of the Pro12Ala polymorphism (rs1801282) of peroxisome proliferator-activated receptor gamma (PPARgamma) is protective against type 2 diabetes (T2DM). Resistin, secreted from adipocytes, causes insulin resistance in rodents. Resistin gene expression is reduced by the PPARgamma ligand. We previously reported that subjects with the G/G genotype of a resistin gene single nucleotide polymorphism (SNP) at -420 (rs1862513) had the highest circulating resistin levels, followed by C/G and C/C. The aim of this study was to determine the relationship among PPARgamma Pro12Ala polymorphism, resistin SNP-420, and plasma resistin.lld:pubmed
pubmed-article:19178525pubmed:languageenglld:pubmed
pubmed-article:19178525pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19178525pubmed:citationSubsetIMlld:pubmed
pubmed-article:19178525pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19178525pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19178525pubmed:statusMEDLINElld:pubmed
pubmed-article:19178525pubmed:monthSeplld:pubmed
pubmed-article:19178525pubmed:issn1365-2265lld:pubmed
pubmed-article:19178525pubmed:authorpubmed-author:NishidaWataru...lld:pubmed
pubmed-article:19178525pubmed:authorpubmed-author:NakuraJunJlld:pubmed
pubmed-article:19178525pubmed:authorpubmed-author:YamadaKazuyaKlld:pubmed
pubmed-article:19178525pubmed:authorpubmed-author:OsawaHaruhiko...lld:pubmed
pubmed-article:19178525pubmed:authorpubmed-author:OnumaHiroshiHlld:pubmed
pubmed-article:19178525pubmed:authorpubmed-author:OchiMasaakiMlld:pubmed
pubmed-article:19178525pubmed:authorpubmed-author:OhashiJunJlld:pubmed
pubmed-article:19178525pubmed:authorpubmed-author:MakinoHideich...lld:pubmed
pubmed-article:19178525pubmed:authorpubmed-author:TabaraYasuhar...lld:pubmed
pubmed-article:19178525pubmed:authorpubmed-author:KoharaKatsuhi...lld:pubmed
pubmed-article:19178525pubmed:authorpubmed-author:MikiTetsuroTlld:pubmed
pubmed-article:19178525pubmed:authorpubmed-author:KawamotoRyuic...lld:pubmed
pubmed-article:19178525pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19178525pubmed:volume71lld:pubmed
pubmed-article:19178525pubmed:ownerNLMlld:pubmed
pubmed-article:19178525pubmed:authorsCompleteYlld:pubmed
pubmed-article:19178525pubmed:pagination341-5lld:pubmed
pubmed-article:19178525pubmed:meshHeadingpubmed-meshheading:19178525...lld:pubmed
pubmed-article:19178525pubmed:meshHeadingpubmed-meshheading:19178525...lld:pubmed
pubmed-article:19178525pubmed:meshHeadingpubmed-meshheading:19178525...lld:pubmed
pubmed-article:19178525pubmed:meshHeadingpubmed-meshheading:19178525...lld:pubmed
pubmed-article:19178525pubmed:meshHeadingpubmed-meshheading:19178525...lld:pubmed
pubmed-article:19178525pubmed:meshHeadingpubmed-meshheading:19178525...lld:pubmed
pubmed-article:19178525pubmed:meshHeadingpubmed-meshheading:19178525...lld:pubmed
pubmed-article:19178525pubmed:meshHeadingpubmed-meshheading:19178525...lld:pubmed
pubmed-article:19178525pubmed:meshHeadingpubmed-meshheading:19178525...lld:pubmed
pubmed-article:19178525pubmed:meshHeadingpubmed-meshheading:19178525...lld:pubmed
pubmed-article:19178525pubmed:meshHeadingpubmed-meshheading:19178525...lld:pubmed
pubmed-article:19178525pubmed:meshHeadingpubmed-meshheading:19178525...lld:pubmed
pubmed-article:19178525pubmed:year2009lld:pubmed
pubmed-article:19178525pubmed:articleTitlePPARgamma Pro12Ala Pro/Pro and resistin SNP-420 G/G genotypes are synergistically associated with plasma resistin in the Japanese general population.lld:pubmed
pubmed-article:19178525pubmed:affiliationDepartment of Molecular and Genetic Medicine, Ehime University Graduate School of Medicine, Toon, Ehime, Japan. harosawa@m.ehime-u.ac.jplld:pubmed
pubmed-article:19178525pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19178525pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:5468entrezgene:pubmedpubmed-article:19178525lld:entrezgene
entrez-gene:56729entrezgene:pubmedpubmed-article:19178525lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:19178525lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:19178525lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:19178525lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:19178525lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19178525lld:pubmed